XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 735-740

  Ooi, Nicola ^a   Miller, Keith ^a   Hobbs, Joanne ^a   Rhys Williams, William ^b   Love, William ^b   Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Destiny Pharma Ltd   (United Kingdom)

Author keywords

Drug action; Membrane integrity; Membrane permeability; Staphylococcus aureus

Indexed keywords

ADENOSINE TRIPHOSPHATE; BACTERIAL DNA; BACTERIAL RNA; BACTERICIDE; CETRIMIDE; CIPROFLOXACIN; DAPTOMYCIN; FLUORESCENT DYE; MOXIFLOXACIN; NISIN; POTASSIUM ION; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; VALINOMYCIN; VANCOMYCIN; XF 73;

ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DNA SYNTHESIS; ISOTOPE LABELING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POTASSIUM TRANSPORT; PROTEIN SYNTHESIS; RNA SYNTHESIS; STAPHYLOCOCCUS AUREUS;

ADENOSINE TRIPHOSPHATE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOMASS; CELL MEMBRANE; COLONY COUNT, MICROBIAL; CYTOSOL; DNA, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR STRUCTURE; PORPHYRINS; POTASSIUM; PROTEIN BIOSYNTHESIS; RADIOISOTOPES; RNA, BACTERIAL; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION, GENETIC;

EID: 70349442444     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp299     Document Type: Article

References (14)

1. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-64.
2. Payne DJ, Gwynn MN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev Drug Disc 2007; 6: 29-40.
3. Love W, Rhys-Williams W, Hayter I et al. XF-73, a novel antimicrobial with broad-ranging Gram-positive antibacterial activity. Clin Microbiol Infect 2008; 14: S130-1.
4. Rhys-Williams W, Love W, Hayter I et al. XF-73: A novel antimicrobial - investigation of the change in MIC against multiple MRSA strains during a 55-passage study. Clin Microbiol Infect 2008; 14: S130.
5. Farrell DJ, Love W, Rhys-Williams W et al. XF-73: A new antimicrobial drug - comparison with mupirocin for the development of mutational resistance against MRSA in a 55-passage study. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy and the Forty-sixth Meeting of the Infectious Disease Society of America, Washington, DC, 2008. Abstract F1-3971, p. 322. American Society for Microbiology, Washington, DC, USA.
6. B modulates virulence determinant expression and stress resistance: Characterization of a functional rsbU strain from Staphylococcus aureus 8325-4. J Bacteriol 2002; 184: 5457-67.
7. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27 (Suppl D): 1-50.
8. Cherrington CA, Hinton M, Chopra I. Effect of short chain organic acids on macromolecular synthesis in Escherichia coli. J Appl Bacteriol 1990; 68: 69-74.
9. Hilliard JJ, Goldschmidt RM, Licata L et al. Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob Agents Chemother 1999; 43: 1693-9.
10. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1791-2.
11. O'Neill AJ, Chopra I. Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol 2006; 59 664-76.
12. Hobbs JK, Miller K, O'Neill AJ et al. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 2008; 62: 1003-8.
13. Gale EF, Cundliffe E, Reynolds PE et al. The Molecular Basis of Antibiotic Action. Second Edition. John Wiley, London, 1981.
14. O'Neill AJ, Chopra I. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin Invest Drugs 2004; 13: 1045-63.